BioCentury
ARTICLE | Company News

Meristem Therapeutics SA, Stallergenes SA deal

June 30, 2003 7:00 AM UTC

Under a three-year deal, Meristem will perform feasibility studies for allergen immunotherapy company Stallergenes to determine if industrial-scale production of two recombinant dust mite allergens ca...